Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study

Magnus Ekström, Hans Bornefalk, C. Magnus Sköld, Christer Janson, Anders Blomberg, Jacob Sandberg, Anna Bornefalk-Hermansson, David C. Currow, Miriam J. Johnson, Josefin Sundh

Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020
Journal Issue: March
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Magnus Ekström, Hans Bornefalk, C. Magnus Sköld, Christer Janson, Anders Blomberg, Jacob Sandberg, Anna Bornefalk-Hermansson, David C. Currow, Miriam J. Johnson, Josefin Sundh. Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study. Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-term predictors of lung function decrease in asthmatics: a 9 year follow-up study
Source: Eur Respir J 2006; 28: Suppl. 50, 145s
Year: 2006

Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021

Does daily SMS increase adherence to asthma treatment? A three months follow-up study
Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Year: 2009


Decline in function in preclinical COPD patients: a 6 years follow up study.
Source: International Congress 2017 – Assessing the functional status of patients with COPD
Year: 2017



Trajectory of patient-reported outcomes (PROMs) up to 6 months after hospitalization for SARS-CoV-2
Source: Virtual Congress 2021 – Long COVID - 19
Year: 2021


Lung function abnormalities in asthmatic children (a 3-5 year follow-up study)
Source: Eur Respir J 2001; 18: Suppl. 33, 120s
Year: 2001

Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study)
Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects
Year: 2008


Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018




Pharmacoeconomic evaluation of COPD: A 1 year follow-up study
Source: Annual Congress 2010 - Influence of delivery of care on outcome parameters: therapy is more than medication prescription
Year: 2010

Clinical outcomes and quality of life of COVID-19 survivors: a follow-up of 3 months post hospital discharge
Source: Virtual Congress 2021 – Pulmonary rehabilitation in the COVID-19 era
Year: 2021


Severe COVID-19 pneumonia: clinical, functional, and imaging outcomes at 4 months
Source: Virtual Congress 2021 – Chronic COVID - 19
Year: 2021



COVID-19: Is pulmonary damage present after 10 weeks follow-up?
Source: Virtual Congress 2021 – Chronic COVID - 19
Year: 2021



COPD eDiary compliance: Comparison of age, symptom score, duration in clinical trial and country of origin
Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD
Year: 2010


Which method is effective in patient with asthma to guide the treatment? (2 year follow-up study)
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

No severe exacerbation with 6 months of high-intensity interval training in the REPLACE study. Preliminary data.
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019

Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results
Source: Eur Respir J 2004; 24: Suppl. 48, 244s
Year: 2004

Clinical indicators of treatment response to Mepolizumab at 12 weeks
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020


Evaluation of asthma control and quality of life after 6 months of treatment with FDC Budesonide/Formoterol-BOREAS study.
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019


Pulmonary function and tomographic features of COVID-19 survivors 2 months after hospital discharge: a cohort study
Source: Virtual Congress 2021 – Long COVID - 19
Year: 2021


Cardiopulmonary exercise testing to assess persistent symptoms at 6 months in people with COVID-19 who survived hospitalisation – A pilot study.
Source: Virtual Congress 2021 – Assessing the impact of COVID-19 on lung function
Year: 2021